← Back to Clinical Trials
Recruiting Phase 4 NCT04913649

NCT04913649 Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04913649
Status Recruiting
Phase Phase 4
Sponsor dr. P. Noordzij
Condition Iron Deficiency Anemia
Study Type INTERVENTIONAL
Enrollment 310 participants
Start Date 2021-09-23
Primary Completion 2026-11

Trial Parameters

Condition Iron Deficiency Anemia
Sponsor dr. P. Noordzij
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 310
Sex ALL
Min Age 70 Years
Max Age N/A
Start Date 2021-09-23
Completion 2026-11
Interventions
Ferric Derisomaltose 100 MG/MLSodium chloride

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Postoperative anemia is common in cardiac surgery with cardiopulmonary bypass. Iron deficiency delays the recovery from postoperative anemia and may negatively affect the postoperative trajectory of cardiac surgery patients. The objective of the study is to determine the effect of treatment of postoperative iron deficiency anemia with intravenous iron on disability 90 days after surgery. This will be evaluated in a randomized placebo-controlled double blind two-center trial in which 310 elective cardiac surgery patients will be included.

Eligibility Criteria

Inclusion Criteria: * Mentally competent with age ≥ 70 years * Elective AVR or CABG surgery * Expected uncomplicated postoperative trajectory, defined as: * No inotropic agents or ventilation at time of final inclusion (POD 1) * Expected discharge to general ward at POD 1 * Moderate postoperative IDA, defined as: * Hb between 85 and 110 g/L and * Ferritin \<100 µg/L or * Iron saturation (TSAT) \< 20% Exclusion Criteria: * Medical history of iron overload/haemochromatosis * Medical history of liver cirrhosis or ALT/AST value in blood serum triple of normal value (female patients: ALT \>120, AST \>105 U/L. Male patients: ALT\>150, AST\>135 U/L) * Severe renal failure (eGFR\<15ml/min/1.73m2) * Recent treatment with IVI (\<12 weeks prior) * Serious or severe allergic reaction to IVI in medical history * Severe asthma or eczema in medical history (atopic constitution)

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology